RxDoctor Payments Data

Laura Wagner, MD

Dermatology · Chesterfield, MONPI 1669445060

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 1,067 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.

$16,044in general payments, 2019–2025

Across 1,067 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • UCB, Inc.$1K
  • Johnson & Johnson$1K
  • plus $6K from 22 others

What the payments were for

  • Food & beverage$15,94299%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,044 in reported general payments places this provider in the 85th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$212,626
Medicare patients
916
Services billed
4,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab15$131,611
OtezlaApremilast16$57,331
AdbryTralokinumab-Ldrm13$49,105
Dupixent PenDupilumab12$44,889
Fluorouracil58$3,386
Clobetasol Propionate64$3,330
Tretinoin32$2,102
Triamcinolone Acetonide138$1,489
ValacyclovirValacyclovir Hcl54$1,460
Metronidazole25$1,115
Azelaic Acid18$991
Ketoconazole87$943
Clindamycin Phosphate30$835
Desonide12$691
Imiquimod14$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,662$57,33116 claims
LEO Pharma Inc.Adbry$513$49,10513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 263 dermatology providers in Missouri.

Other dermatology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →